CLAIMS

1. An isolated antibody, or an antigen binding fragment thereof, that is specific for a complex of human cytomegalovirus (hCMV) proteins UL130 and UL131A, wherein the complex forms the epitope recognized by the antibody or fragment, comprising:

(a) heavy chain CDR1, CDR2, and CDR3 sequences as set forth in SEQ ID NOs: 49, 50, and 51, respectively, and light chain CDR1, CDR2, and CDR3 sequences as set forth in SEQ ID NOs: 52, 53, and 54, respectively;

(b) heavy chain CDR1, CDR2, and CDR3 sequences as set forth in SEQ ID NOs: 1, 2, and 3, respectively, and light chain CDR1, CDR2, and CDR3 sequences as set forth in SEQ ID NOs: 4, 5, and 6, respectively;

(c) heavy chain CDR1, CDR2, and CDR3 sequences as set forth in SEQ ID NOs: 33, 34, and 35, respectively, and light chain CDR1, CDR2, and CDR3 sequences as set forth in SEQ ID NOs: 36, 37, and 38, respectively;

(d) heavy chain CDR1, CDR2, and CDR3 sequences as set forth in SEQ ID NOs: 17, 18, and 19, respectively, and light chain CDR1, CDR2, and CDR3 sequences as set forth in SEQ ID NOs: 20, 21, and 22, respectively; or

(e) heavy chain CDR1, CDR2, and CDR3 sequences as set forth in SEQ ID NOs: 113, 114, and 115, respectively, and light chain CDR1, CDR2, and CDR3 sequences as set forth in SEQ ID NOs: 116, 117, and 118, respectively.

2. ~~An isolated~~The antibody, or ~~an~~ antigen binding fragment ~~there~~of claim 1~~, that is specific for a complex of human cytomegalovirus (hCMV) proteins UL130 and UL131A, wherein the complex forms the epitope recognized by the antibody or fragment,~~ comprising:

(a) a heavy chain variable region sequence having at least 85% sequence identity to SEQ ID NO: 61 and a light chain variable region sequence having at least 85% sequence identity to SEQ ID NO: 62;

(b) a heavy chain variable region sequence having at least 85% sequence identity to SEQ ID NO: 13 and a light chain variable region sequence having at least 85% sequence identity to SEQ ID NO: 14;

(c) a heavy chain variable region sequence having at least 85% sequence identity to SEQ ID NO: 45 and a light chain variable region sequence having at least 85% sequence identity to SEQ ID NO: 46;

(d) a heavy chain variable region sequence having at least 85% sequence identity to

(d) SEQ ID NOs: 290 and 291 ;

(e) SEQ ID NOs: 294 and 291;

(f) SEQ ID NOs: 357 and 291;

(g) SEQ ID NOs: 308 and 309;

(h) SEQ ID NOs: 314 and 309;

(i) SEQ ID NOs: 367 and 368;

(j) SEQ ID NOs: 13 and 14;

(k) SEQ ID NOs: 45 and 46;

(l) SEQ ID NOs: 258 and 259;

(m) SEQ ID NOs: 242 and 243;

(n) SEQ ID NOs: 228 and 229;

(o) SEQ ID NOs: 77 and 78;

(p) SEQ ID NOs: 141 and 142;

(q) SEQ ID NOs: 93 and 94;

(r) SEQ ID NOs: 157 and 158;

(s) SEQ ID NOs: 109 and 110;

(t) SEQ ID NOs: 170 and 171;

or an antibody which binds to the same epitope as the antibody of any one of (a) - (t).

16. The composition of claim 14, wherein the second antibody has heavy and light chains which respectively comprise SEQ ID NOs: 328 and 329, or SEQ ID NOs: 334 and 329.

17. Use of the antibody or fragment of any one of claims 1-8, the nucleic acid of claim 9 or 10, or the cell of claim 12, in the manufacture of a medicament for the treatment of hCMV infection.

18. A method for producing the antibody or fragment of any one of claims 1-8, comprising (i) culturing the cell of claim 12 and (ii) isolating the antibody or fragment.

19. An *in vitro* method of inhibiting hCMV infection in a cell, comprising contacting the cell with the antibody or fragment of any one of claims 1-8, wherein hCMV infection is inhibited.